Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Pharma Aids's 5-Year ROIIC % for the quarter that ended in Jun. 2025 was 5.52%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Pharma Aids's 5-Year ROIIC % or its related term are showing as below:
DHA:PHARMAID's 5-Year ROIIC % is ranked better than 58.8% of 733
companies
in the Medical Devices & Instruments industry
Industry Median: 0.92
vs DHA:PHARMAID: 5.52
Pharma Aids (DHA:PHARMAID) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Pharma Aids 5-Year ROIIC % Related Terms
Pharma Aids 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Pharma Aids's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, MDLN: 5-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Pharma Aids's 5-Year ROIIC % falls into.
Pharma Aids's 5-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( 66.167196 (Jun. 2025) - 53.81775 (Jun. 2020) )
/
( 495.736 (Jun. 2025) - 271.909 (Jun. 2020) )
=
12.349446
/
223.827
=
5.52%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Pharma Aids (DHA:PHARMAID) has a 5-Year ROIIC % of 5.52 as of Jun. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Pharma Aids and its competitors. According to the industry distribution chart, Pharma Aids ranks #302 out of 733 companies in the Medical Devices & Instruments industry, placing it in the top 41.2%.
Is Pharma Aids' 5-Year ROIIC % too high?
Pharma Aids' current 5-Year ROIIC % is 5.52. The Medical Devices & Instruments industry median 5-Year ROIIC % is 0.92. Pharma Aids' value of 5.52 is 500% above this industry median. Based on the distribution chart, Pharma Aids ranks #302 out of 733 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' 5-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #302 out of 733 companies for 5-Year ROIIC %. This puts Pharma Aids in the upper half of its industry. The industry median 5-Year ROIIC % is 0.92. Pharma Aids' value of 5.52 is 500% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 0.92, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current 5-Year ROIIC % of 5.52 is 500% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Pharma Aids and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 0.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current 5-Year ROIIC % is 5.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT762.98, compared to a current price of BDT607.90 — trading 20.3% below its estimated fair value. The current 5-Year ROIIC % is 5.52 and 500% above the Medical Devices & Instruments industry median of 0.92. Pharma Aids' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current 5-Year ROIIC % is 5.52 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT607.90 is trading 20.3% below its estimated GF Value™ of BDT762.98.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
5-Year ROIIC %: 5.52
GF Value™: BDT762.98 vs. price of BDT607.90 (20.3% below fair value)
Industry Position: 500% above the Medical Devices & Instruments median (#302 of 733)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
